NCT03352739 (FANTASIA) is a NA clinical trial of DBS of the fornix, power on in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing.

Who is sponsoring NCT03352739?

NCT03352739 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT03352739?

Interventions in NCT03352739: DBS of the fornix, power on, DBS of the NbM, power on, DBS of the fornix, power off, DBS of the NbM, power off.

What condition does NCT03352739 study?

NCT03352739 studies Alzheimer Disease.

Is NCT03352739 still recruiting?

NCT03352739 is currently status unknown. Last updated 11 January 2018.

Last reviewed 2018-01-11 · How we verify

NCT03352739: FANTASIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fornix and NbM as Targets of Stimulation In Alzheimer's Disease

Status unknown NA Last updated 11 January 2018

What this trial tests

NA trial testing DBS of the fornix, power on in Alzheimer Disease in 30 participants. Status unknown.

Timeline

1 December 2017

Primary endpoint
1 December 2019

1 December 2020

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	1 December 2017
Primary completion	1 December 2019
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

DBS of the fornix, power on
DBS of the NbM, power on
DBS of the fornix, power off
DBS of the NbM, power off

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 45 to 75, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to evaluate the efficacy and safety of the DBS to the fornix/NbM among patients who are diagnosed as AD according to a series of evaluations including cerebrospinal fluid (CSF) biomarkers and molecular imaging examinations; The secondary goal is to compare the efficacy among the two treatment groups of different targets.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
A circuit view of deep brain stimulation in Alzheimer's disease and the possible mechanisms.
Yu D, Yan H, Zhou J, Yang X, et al · · 2019 · cited 34× · PMID 31395077 · DOI 10.1186/s13024-019-0334-4
Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991
Opening the debate on deep brain stimulation for Alzheimer disease - a critical evaluation of rationale, shortcomings, and ethical justification.
Bittlinger M, Müller S. · · 2018 · cited 13× · PMID 29886845 · DOI 10.1186/s12910-018-0275-4

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03352739 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 11 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03352739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing